We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01140425
Recruitment Status : Completed
First Posted : June 9, 2010
Last Update Posted : December 23, 2010
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to assess the affect that PF-00232798 has on QT interval. A prolonged QT interval is a risk factor for arrhythmias.

Condition or disease Intervention/treatment Phase
Healthy Drug: PF-00232798 Drug: Placebo Drug: Moxifloxacin Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Multiple Dose, Placebo And Active Controlled, 4-Way Crossover Study To Evaluate The Effect Of A Multiple Oral Dose of PF-00232798 On Qt Intervals In Healthy Subjects
Study Start Date : July 2010
Primary Completion Date : December 2010
Study Completion Date : December 2010
Arms and Interventions

Arm Intervention/treatment
Experimental: PF-00232798 supratherapeutic dose
PF-00232798 supratherapeutic dose
Drug: PF-00232798
600 mg oral solution once daily x 7 days
Experimental: PF-00232798 therapeutic dose
PF-00232798 therapeutic dose
Drug: PF-00232798
300 mg oral solution once daily x 7 days
Placebo Comparator: Placebo for PF-00232798
Placebo for PF-00232798
Drug: Placebo
Oral solution once daily x 7 days
Active Comparator: Moxifloxacin
Drug: Moxifloxacin
400 mg tablet single dose

Outcome Measures

Primary Outcome Measures :
  1. QTc, using Fridericia's correction method (QTcF) at each time point of PF-00232798 and placebo on Day 7. [ Time Frame: 7 days ]

Secondary Outcome Measures :
  1. QTcF, or any other appropriate correction method at each postdose time point of moxifloxacin on Day 7 [ Time Frame: 7 days ]
  2. QTcB or any other appropriate correction method at each postdose time point of PF-00232798 and placebo on Day 7 [ Time Frame: 7 days ]
  3. Pharmacokinetic endpoints for PF-00232798 (Tmax, Cmax, Cτ, and AUClast) [ Time Frame: 7 days ]
  4. Safety and toleration assessed by spontaneous reporting of adverse events, vital signs, 12-lead ECG and laboratory safety assessments [ Time Frame: 7 days ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male and/or female subjects of non-childbearing potential between the ages of 21 and 55 years, inclusive.
  • Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).

Exclusion Criteria:

  • Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.
  • 12-lead ECG demonstrating QTc >450 msec at screening.
  • Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
  • History of orthostatic symptoms or orthostatic hypotension at screening.
  • Pregnant or nursing females; females of childbearing potential.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01140425

Pfizer Investigational Site
Singapore, Singapore, 188770
Sponsors and Collaborators
ViiV Healthcare
Study Director: Pfizer CT.gov Call Center Pfizer
More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT01140425     History of Changes
Other Study ID Numbers: A7691017
First Posted: June 9, 2010    Key Record Dates
Last Update Posted: December 23, 2010
Last Verified: December 2010

Keywords provided by Pfizer:

Additional relevant MeSH terms:
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Nucleic Acid Synthesis Inhibitors